AC Immune SA (NASDAQ: ACIU)

AC Immune SA is a clinical stage biopharmaceutical company focused on developing precision medicine approaches for neurodegenerative diseases. The company leverages its dual proprietary technology platforms, SupraAntigen and Morphomer, to create a pipeline of therapeutic and diagnostic candidates targeting proteinopathies associated with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

AC Immune generates revenue primarily through upfront payments, milestone payments, and royalty streams from collaboration and licensing agreements with major pharmaceutical partners. These agreements support the development and potential commercialization of its product candidates, including active immunotherapies and diagnostic imaging agents.

The company operates through the following segments: Therapeutics and Diagnostics.

• The Therapeutics segment focuses on the discovery and development of active immunotherapies and small molecule drugs designed to modify disease progression in neurodegenerative conditions. This includes programs targeting amyloid beta, tau, and alpha-synuclein pathologies, such as ACI-24.060 for Alzheimer's disease and Down syndrome, ACI-35.030 in collaboration with Janssen for preclinical Alzheimer's disease, and ACI-7104.056 for Parkinson's disease, as well as small molecule inhibitors like ACI-19764 targeting the NLRP3 inflammasome pathway.

• The Diagnostics segment involves the development of positron emission tomography (PET) tracers to detect and quantify pathological protein aggregates in the brain. Key candidates include PI-2620 for tau pathology in Alzheimer's disease, ACI-12589 and ACI-15916 for alpha-synuclein in multiple system atrophy and Parkinson's disease, and ACI-19626 for TDP-43 pathology in conditions such as amyotrophic lateral sclerosis and frontotemporal dementia.

AC Immune occupies a differentiated position in the neurodegenerative disease space due to its proprietary technology platforms that enable conformational specificity in targeting misfolded proteins. While it faces competition from larger pharmaceutical companies developing monoclonal antibodies and small molecule therapies, its active immunotherapy approach offers potential advantages in durability of immune response, dosing convenience, and cost-effectiveness compared to passive immunization strategies.

The company serves patients, healthcare providers, and pharmaceutical collaborators. Its therapeutic and diagnostic candidates are intended for individuals with or at risk of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Down syndrome-related Alzheimer's, multiple system atrophy, and frontotemporal lobar degeneration.